Literature DB >> 4547783

Substrates of Hageman factor. I. Isolation and characterization of human factor XI (PTA) and inhibition of the activated enzyme by alpha 1-antitrypsin.

L W Heck, A P Kaplan.   

Abstract

Unactivated partial thromboplastin antecedent (PTA) has been purified by sequential chromatography of plasma on quaternary aminoethyl Sephadex, sulphoprophyl Sephadex, Sephadex G-150, and passage over an anti-IgG immunoadsorbant. The preparation gave a single band after alkaline disc gel electrophoresis, sodium dodecyl sulfate (SDS) gel electrophoresis and isoelectric focusing in acrylamide gels and was found to have a mol wt of 175,000 by gel filtration, 163,000 by SDS gel electrophoresis, and an isoelectric point of 8.8-9.4 (peak 9.0-9.1). Pre-PTA was activated directly by activated Hageman factor or by Hageman factor prealbumin fragments. Its coagulant activity was inhibited by DFP, soybean trypsin inhibitor and trasylol but not by lima bean trypsin inhibitor or ovomucoid trypsin inhibitor indicating that activated PTA possesses the same inhibition profile utilizing these reagents as does plasma kallikrein. A major plasma inhibitor of activated PTA was found to be a 65,000 mol wt alpha-globulin which was isolated free of alpha(1)-chymotrypsin inhibitor, inter alpha-trypsin inhibitor, alpha(2)-macroglobulin, and the other known inhibitors of activated PTA, the activated first component of complement (C1 INH), and antithrombin III. Its physicochemical properties were identical to alpha(1)-antitrypsin, and it was absent in alpha(1)-antitrypsin-deficient plasma thereby identifying this PTA inhibitor as alpha(1)-antitrypsin.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4547783      PMCID: PMC2139762          DOI: 10.1084/jem.140.6.1615

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  22 in total

1.  Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation.

Authors:  A S Weiss; J I Gallin; A P Kaplan
Journal:  J Clin Invest       Date:  1974-02       Impact factor: 14.808

2.  Plasminogen: purification from human plasma by affinity chromatography.

Authors:  D G Deutsch; E T Mertz
Journal:  Science       Date:  1970-12-04       Impact factor: 47.728

3.  Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator.

Authors:  C D Forbes; J Pensky; O D Ratnoff
Journal:  J Lab Clin Med       Date:  1970-11

4.  A pre-albumin activator of prekallikrein.

Authors:  A P Kaplan; K F Austen
Journal:  J Immunol       Date:  1970-10       Impact factor: 5.422

5.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

6.  Method of purification and properties of anti-XIa (inhibitor of the contact product).

Authors:  J Niemetz; H L Nossel
Journal:  Thromb Diath Haemorrh       Date:  1967-05-31

7.  Separation of plasma thromboplastin antecedent from kallikrein by the plasma 2 -macroglobulin, kallikrein inhibitor.

Authors:  P C Harpel
Journal:  J Clin Invest       Date:  1971-10       Impact factor: 14.808

8.  Inhibitors of kallikrein in human plasma.

Authors:  D J McConnell
Journal:  J Clin Invest       Date:  1972-07       Impact factor: 14.808

9.  A prealbumin activator of prekallikrein. II. Derivation of activators of prekallikrein from active Hageman factor by digestion with plasmin.

Authors:  A P Kaplan; K F Austen
Journal:  J Exp Med       Date:  1971-04-01       Impact factor: 14.307

10.  A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein.

Authors:  A P Kaplan; A B Kay; K F Austen
Journal:  J Exp Med       Date:  1972-01       Impact factor: 14.307

View more
  17 in total

Review 1.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

2.  Mechanisms and specificity of factor XIa and trypsin inhibition by protease nexin 2 and basic pancreatic trypsin inhibitor.

Authors:  Duraiswamy Navaneetham; Dipali Sinha; Peter N Walsh
Journal:  J Biochem       Date:  2010-07-20       Impact factor: 3.387

3.  Purification of high molecular weight kininogen and the role of this agent in blood coagulation.

Authors:  H Saito
Journal:  J Clin Invest       Date:  1977-09       Impact factor: 14.808

4.  Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein.

Authors:  H L Meier; J V Pierce; R W Colman; A P Kaplan
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

Review 5.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

6.  Association of factor XI and high molecular weight kininogen in human plasma.

Authors:  R E Thompson; R Mandle; A P Kaplan
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

7.  Regulation of factor XIa activity by platelets and alpha 1-protease inhibitor.

Authors:  P N Walsh; D Sinha; F Kueppers; F S Seaman; K B Blankstein
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

8.  Mechanisms of activation of the classical pathway of complement by Hageman factor fragment.

Authors:  B Ghebrehiwet; B P Randazzo; J T Dunn; M Silverberg; A P Kaplan
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

9.  Isolation and characterization of alpha-1-antitrypsin from rhesus-monkey serum.

Authors:  R W Berninger; R K Mathis
Journal:  Biochem J       Date:  1976-10-01       Impact factor: 3.857

10.  Acquired antibody to factor XI in a patient with congenital factor XI deficiency.

Authors:  D M Stern; H L Nossel; J Owen
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.